Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Endocrine Pathology
Published in: Endocrine Pathology 3/2006

01-09-2006 | Clinical Research

Expression of proliferation markers in human pituitary incidentalomas

Authors: Masanori Suzuki, Takeo Minematsu, Kenichi Oyama, Shigeyuki Tahara, Shunsuke Miyai, Naoko Sanno, Dr. Robert Yoshiyuki Osamura, MD, PhD, Akira Teramoto

Published in: Endocrine Pathology | Issue 3/2006

Login to get access
Metadata
Title
Expression of proliferation markers in human pituitary incidentalomas
Authors
Masanori Suzuki
Takeo Minematsu
Kenichi Oyama
Shigeyuki Tahara
Shunsuke Miyai
Naoko Sanno
Dr. Robert Yoshiyuki Osamura, MD, PhD
Akira Teramoto
Publication date
01-09-2006
Publisher
Humana Press
Published in
Endocrine Pathology / Issue 3/2006
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1385/EP:17:3:263

Other articles of this Issue 3/2006

Endocrine Pathology 3/2006 Go to the issue

Clinical Research

Diagnostic value of differential expression of CK19, galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: An immunohistochemical tissue microarray analysis

Clinical Research

Expression of laminin β2: A novel marker of hypoxia in pituitary adenomas

Clinical Research

BRAF mutation is unusual in chronic lymphocytic thyroiditis-associated papillary thyroid carcinomas and absent in non-neoplastic nuclear atypia of thyroiditis

Clinical Research

Abnormalities in incidentally removed adrenal glands

Animal Model

Lymphocytic insulitis in a juvenile dog with diabetes mellitus

Review

Role of mitochondrial mutations in cancer
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits